Optimization of equipment and methodology for whole-body activity retention measurements in children undergoing targeted radionuclide therapy

被引:23
作者
Chittenden, Sarah J. [1 ]
Pratt, Brenda E. [1 ]
Pomeroy, Kay [1 ]
Black, Peter [1 ]
Long, Clive [1 ]
Smith, Nicholas [1 ]
Buckley, Susan E. [1 ]
Saran, Frank H. [1 ]
Flux, Glenn D. [1 ]
机构
[1] Royal Marsden NHS Fdn Trust, Dept Phys, Sutton SM2 5PT, Surrey, England
关键词
radionuclide therapy; 131]I-MIBG; whole-body dose; whole-body retention measurements;
D O I
10.1089/cbr.2006.315
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Accurate measurements of whole-body activity retention of patients during radionuclide therapy are essential for two reasons: First, they enable the correct radiation protection advice to be given and second, the, v permit the accurate determination of the absorbed whole-body dose delivered during therapy. This, in turn, allows treatment planning to be carried out for future radionuclide therapy on an individual patient basis, and also enables the investigation of the potential correlation of absorbed dose with treatment outcome in groups of patients. There are significant difficulties associated with taking whole-body retention measurements of children, especially when they are very young and/or unwell. It is essential to carry these out in a way that minimises disturbance to the child while still providing good quality data. To accomplish this, we have aimed to optimize the following aspects of the procedure: (i) the environment in which the measurements are performed; (ii) the equipment-which includes the recent installation of a specially designed whole-body activity monitoring system for these patients; and (iii) the methodology for calculating the absorbed dose. These improvements have allowed large numbers of accurate and reproducible whole-body measurements to be collected,following patient administrations. This has enabled the identification of more phases of radionuclide excretion during therapy than had previously been observed. These data have been used for radiation protection advice and treatment planning. Two (2) patients were given multiple radionuclide treatments and we were able to compare the whole-body doses delivered.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 11 条
[1]  
BUCKLEY SE, 2007, IN PRESS CANC BIOTHE
[2]  
Cristy M., 1987, TN Oak Ridge Natl. Lab, pV1
[3]   Whole-body dosimetry for targeted radionuclide therapy using spectral analysis [J].
Divoli, A ;
Spinelli, A ;
Chittenden, S ;
Dearnaley, D ;
Flux, G .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (01) :66-71
[4]   Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG [J].
Flux, GD ;
Guy, MJ ;
Papavasileiou, P ;
South, C ;
Chittenden, SJ ;
Flower, MA ;
Meller, ST .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (01) :81-87
[5]   Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy [J].
Flux, GD ;
Guy, MJ ;
Beddows, R ;
Pryor, M ;
Flower, MA .
PHYSICS IN MEDICINE AND BIOLOGY, 2002, 47 (17) :3211-3223
[6]   Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma [J].
Gaze, MN ;
Chang, YC ;
Flux, GD ;
Mairs, RJ ;
Saran, FH ;
Meller, ST .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (02) :195-199
[7]   Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma:: updated results and long-term follow-up of the University of Michigan experience [J].
Kaminski, MS ;
Estes, J ;
Zasadny, KR ;
Francis, IR ;
Ross, CW ;
Tuck, M ;
Regan, D ;
Fisher, S ;
Gutierrez, J ;
Kroll, S ;
Stagg, R ;
Tidmarsh, G ;
Wahl, RL .
BLOOD, 2000, 96 (04) :1259-1266
[8]  
Loevinger R., 1988, MIRD primer for absorbed dose calculations
[9]  
Matthay KK, 2001, J NUCL MED, V42, P1713
[10]   Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours [J].
Monsieurs, MA ;
Thierens, HM ;
Vral, A ;
Brans, B ;
De Ridder, L ;
Dierckx, RA .
NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (04) :367-374